首页> 外国专利> Use of the ratio of ventricular enlargement for the treatment of Alzheimer's disease with intravenous immunoglobulin and Method for evaluating the therapeutic efficacy

Use of the ratio of ventricular enlargement for the treatment of Alzheimer's disease with intravenous immunoglobulin and Method for evaluating the therapeutic efficacy

机译:心室扩大比在静脉注射免疫球蛋白治疗阿尔茨海默氏病中的用途和评估疗效的方法

摘要

Requirement 1: methods of treatment in patients with Alzheimer's disease, including (a) sequential steps to determine the volume of the patient's central ventricle through magnetic resonance imaging (IRM),Therefore, a reference value of ventricular volume was obtained; (b) a therapeutic agent to keep the brain was used for the treatment of Alzheimer's disease for the first time; (c) the ventricular volume of the brain was determined by IRM. Therefore, the first intermediate value of ventricular volume was obtained; (d) the intermediate value of stage (c) was compared with the reference value of stage (a);(e) When level (d) indicates an increase from the reference value to the first intermediate value, and the increase is equal to or greater than the expected increase in ventricular volume of Alzheimer's patients, but without treatment, the use of brain preservation therapy agent with increased dose or frequency is increased Treatment of the disease within the same period as the first period,Or maintain the use of brain maintaining dose or frequency therapeutics when (d) indicates that there is no increase from the reference value to the first intermediate value, or that the increase is less than the increaseIt is expected to be within the ventricular volume of patients with Alzheimer's, but not treated for the same period of time as the first cycle.There, the therapeutic agent is a therapeutic agent that protects the brain through immunoglobulins. Claim 7: method of claim 1, wherein the therapeutic agent is immunoglobulin injection (lglv).
机译:要求1:阿尔茨海默氏病患者的治疗方法,包括:(a)通过磁共振成像(IRM)确定患者中央心室容积的连续步骤,因此,可获得心室容积的参考值; (b)首次将保持大脑的治疗剂用于阿尔茨海默氏病的治疗; (c)脑室容量是由IRM确定的。因此,获得了心室容积的第一中间值。 (d)将阶段(c)的中间值与阶段(a)的参考值进行比较;(e)当级别(d)表示从参考值到第一中间值的增加时,该增加等于或大于阿尔茨海默氏症患者预期的心室容量增加,但未经治疗,增加剂量或频率的脑保护治疗剂的使用增加与第一期相同的时期内对该疾病的治疗,或维持脑的使用当(d)表示从参考值到第一个中间值没有增加,或者增加幅度小于增加幅度时,维持剂量或频率治疗药物预期在阿尔茨海默氏病患者的心室容积内,但未接受治疗在与第一个周期相同的时间段内。治疗剂是通过免疫球蛋白保护大脑的治疗剂。 7.根据权利要求1所述的方法,其中,所述治疗剂是免疫球蛋白注射液(lglv)。

著录项

  • 公开/公告号AR081534A1

    专利类型

  • 公开/公告日2012-10-03

    原文格式PDF

  • 申请/专利号AR2011P101285

  • 发明设计人

    申请日2011-04-14

  • 分类号A61K39/395;A61P25/28;

  • 国家 AR

  • 入库时间 2022-08-21 17:25:36

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号